Medicaid Opioid Treatment Access Hits Record 69%, But Retention Challenges Persist

The expansion of medication-assisted treatment for opioid use disorder has achieved a significant milestone among Medicaid beneficiaries, with uptake rising from 60% in 2018 to 69.1% in 2023. Yet this progress in treatment access masks a troubling trend: the percentage of patients who remain in treatment for at least 180 days has actually declined during the same period, falling from 62.6% to 57.7%.

This paradox—more people starting treatment, but fewer staying in it—raises fundamental questions about the quality and sustainability of care being delivered, even as policymakers celebrate expanded access.

The Access Revolution

Between 2018 and 2023, federal and state governments implemented an unprecedented series of policy changes designed to remove barriers to medication for opioid use disorder. Medicaid expansion in numerous states dramatically increased insurance coverage for low-income Americans with addiction. The elimination of the X-waiver requirement allowed any DEA-registered prescriber to prescribe buprenorphine, effectively doubling the potential prescriber pool overnight. Telehealth flexibilities introduced during the COVID-19 pandemic were extended, allowing patients to initiate treatment via video consultation rather than requiring in-person visits. Restrictions on take-home methadone doses were eased, reducing the burden of daily clinic visits.

These changes worked. Millions of Americans gained access to medications for opioid use disorder who previously faced insurmountable barriers. The 69.1% treatment rate represents genuine progress in a healthcare system that historically made addiction treatment harder to access than nearly any other medical condition.

The Retention Problem

However, the decline in 180-day retention—from 62.6% to 57.7%—suggests that expanded access may be coming at a cost to treatment continuity. The American Society of Addiction Medicine recommends that patients with opioid use disorder remain on medication for at least six months, with many benefiting from indefinite maintenance. Medications like buprenorphine and methadone reduce overdose risk by 50% or more, but these protective effects diminish rapidly after discontinuation.

Several factors may explain why patients are leaving treatment sooner despite easier access. The same telehealth flexibilities that expanded geographic reach may have weakened therapeutic relationships, with brief video check-ins replacing more intensive engagement. The influx of new prescribers following X-waiver elimination includes clinicians with limited addiction medicine training who may lack the expertise to address complex cases involving co-occurring mental health disorders, homelessness, or criminal justice involvement.

Additionally, the behavioral health workforce shortage that predated the pandemic has only intensified. Patients may face long waits for counseling services that complement medication, or find that their prescriber has limited capacity for the intensive case management that supports long-term retention.

The Medicaid Context

Medicaid covers approximately 40% of all medication-assisted treatment nationally, making program policies particularly consequential for the addiction treatment landscape. The program's role as the primary payer for OUD treatment means that retention trends among Medicaid beneficiaries likely reflect broader patterns in how the American healthcare system is responding to the opioid crisis.

The data arrives at a moment of significant policy uncertainty. Congressional Republicans have proposed deep cuts to Medicaid funding, while the Trump administration has moved to restrict federal support for harm reduction programs and consolidate SAMHSA's grant programs. These changes threaten the infrastructure that has supported expanded treatment access, even as the retention data suggests that access alone is insufficient.

Implications for Treatment Quality

The divergence between access and retention metrics highlights a fundamental challenge in addiction medicine: getting people into treatment is necessary but not sufficient for recovery. The 180-day threshold matters because early discontinuation of medication is associated with dramatically elevated overdose risk. Patients who leave treatment within the first six months face mortality rates comparable to those who never initiated treatment at all.

Quality improvement efforts may need to shift focus from simply increasing prescriber capacity to enhancing the services that support long-term engagement. This includes integrated mental health care, housing assistance, peer recovery support, and flexible dosing arrangements that accommodate patients' work schedules and transportation limitations.

Looking Forward

The 69% treatment rate represents a genuine achievement in expanding access to evidence-based care. But the retention decline serves as a reminder that treatment quality cannot be measured by enrollment numbers alone. As policymakers debate the future of Medicaid and addiction services funding, both metrics—access and retention—must inform decision-making.

The opioid crisis has entered a new phase where the challenge is no longer primarily about getting people into treatment, but keeping them there. Meeting this challenge will require sustained investment not just in prescribing capacity, but in the comprehensive services that support long-term recovery.